Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Amgen AMGN

Amgen live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2024 Nov 20, 16:00

MicroStrategy Stock Surges as Bitcoin price rises to fresh record above $94K

Cryptocurrencies
Frances Wang 2024 Nov 20, 16:00

Nasdaq futures decline, Nvidia shares dip following the earnings report

Indices CFD Trading Stocks
Mixed market performance
Neil Wilson 2024 Nov 20, 16:00

Markets Mixed Amid Inflation, Tech Rally, and UK Economic Woes

USD Tech S&P 500
Frances Wang 2024 Nov 19, 16:00

Nvidia shares rallied on AI spending ahead of Nvidia Q3 earnings 2024

NVDA Stocks
Frances Wang 2024 Nov 19, 16:00

Bitcoin price hits record high over $93,800 as Trump rally resumes

Cryptocurrencies
Rising gold prices
Neil Wilson 2024 Nov 19, 16:00

Gold Shines, Bitcoin Surges, and Nvidia Earnings in Focus

Gold Cryptocurrencies
Frances Wang 2024 Nov 18, 16:00

What is the cryptocurrency market doing: Musk's DOGE Role Boosts Dogecoin

Cryptocurrencies
Frances Wang 2024 Nov 18, 16:00

Bitcoin price prediction: BTC May Reach $100K Before New Year

Cryptocurrencies

Info

Spread

1.95

Spread (%)

0.6800 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Donderdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Vrijdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

154739621888

Uitstaande aandelen

537532992

Datum winstcijfer (volgende)

1999-11-22

Div. rend.

2024-12-09

Ex-dividenddatum

2024-11-18

Jaarlijks verwachte dividendpercentage

9

Jaarlijks verwachte dividendrendement

0.0321

Winst per aandeel

7.83

Meer informatie over dit instrument

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat